Cargando…

Environmental Pseudomonads Inhibit Cystic Fibrosis Patient-Derived Pseudomonas aeruginosa

Pseudomonas aeruginosa is an opportunistic pathogen which is evolving resistance to many currently used antibiotics. While much research has been devoted to the roles of pathogenic P. aeruginosa in cystic fibrosis (CF) patients, less is known of its ecological properties. P. aeruginosa dominates the...

Descripción completa

Detalles Bibliográficos
Autores principales: Chatterjee, Payel, Davis, Elizabeth, Yu, Fengan, James, Sarah, Wildschutte, Julia H., Wiegmann, Daniel D., Sherman, David H., McKay, Robert M., LiPuma, John J., Wildschutte, Hans
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5203635/
https://www.ncbi.nlm.nih.gov/pubmed/27881418
http://dx.doi.org/10.1128/AEM.02701-16
_version_ 1782489765608685568
author Chatterjee, Payel
Davis, Elizabeth
Yu, Fengan
James, Sarah
Wildschutte, Julia H.
Wiegmann, Daniel D.
Sherman, David H.
McKay, Robert M.
LiPuma, John J.
Wildschutte, Hans
author_facet Chatterjee, Payel
Davis, Elizabeth
Yu, Fengan
James, Sarah
Wildschutte, Julia H.
Wiegmann, Daniel D.
Sherman, David H.
McKay, Robert M.
LiPuma, John J.
Wildschutte, Hans
author_sort Chatterjee, Payel
collection PubMed
description Pseudomonas aeruginosa is an opportunistic pathogen which is evolving resistance to many currently used antibiotics. While much research has been devoted to the roles of pathogenic P. aeruginosa in cystic fibrosis (CF) patients, less is known of its ecological properties. P. aeruginosa dominates the lungs during chronic infection in CF patients, yet its abundance in some environments is less than that of other diverse groups of pseudomonads. Here, we sought to determine if clinical isolates of P. aeruginosa are vulnerable to environmental pseudomonads that dominate soil and water habitats in one-to-one competitions which may provide a source of inhibitory factors. We isolated a total of 330 pseudomonads from diverse habitats of soil and freshwater ecosystems and competed these strains against one another to determine their capacity for antagonistic activity. Over 900 individual inhibitory events were observed. Extending the analysis to P. aeruginosa isolates revealed that clinical isolates, including ones with increased alginate production, were susceptible to competition by multiple environmental strains. We performed transposon mutagenesis on one isolate and identified an ∼14.8-kb locus involved in antagonistic activity. Only two other environmental isolates were observed to carry the locus, suggesting the presence of additional unique compounds or interactions among other isolates involved in outcompeting P. aeruginosa. This collection of strains represents a source of compounds that are active against multiple pathogenic strains. With the evolution of resistance of P. aeruginosa to currently used antibiotics, these environmental strains provide opportunities for novel compound discovery against drug-resistant clinical strains. IMPORTANCE We demonstrate that clinical CF-derived isolates of P. aeruginosa are susceptible to competition in the presence of environmental pseudomonads. We observed that many diverse environmental strains exhibited varied antagonistic profiles against a panel of clinical P. aeruginosa isolates, suggesting the presence of distinct mechanisms of inhibition among these ecological strains. Understanding the properties of these antagonistic events offers the potential for discoveries of antimicrobial compounds or metabolic pathways important to the development of novel treatments for P. aeruginosa infections.
format Online
Article
Text
id pubmed-5203635
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-52036352017-01-12 Environmental Pseudomonads Inhibit Cystic Fibrosis Patient-Derived Pseudomonas aeruginosa Chatterjee, Payel Davis, Elizabeth Yu, Fengan James, Sarah Wildschutte, Julia H. Wiegmann, Daniel D. Sherman, David H. McKay, Robert M. LiPuma, John J. Wildschutte, Hans Appl Environ Microbiol Environmental Microbiology Pseudomonas aeruginosa is an opportunistic pathogen which is evolving resistance to many currently used antibiotics. While much research has been devoted to the roles of pathogenic P. aeruginosa in cystic fibrosis (CF) patients, less is known of its ecological properties. P. aeruginosa dominates the lungs during chronic infection in CF patients, yet its abundance in some environments is less than that of other diverse groups of pseudomonads. Here, we sought to determine if clinical isolates of P. aeruginosa are vulnerable to environmental pseudomonads that dominate soil and water habitats in one-to-one competitions which may provide a source of inhibitory factors. We isolated a total of 330 pseudomonads from diverse habitats of soil and freshwater ecosystems and competed these strains against one another to determine their capacity for antagonistic activity. Over 900 individual inhibitory events were observed. Extending the analysis to P. aeruginosa isolates revealed that clinical isolates, including ones with increased alginate production, were susceptible to competition by multiple environmental strains. We performed transposon mutagenesis on one isolate and identified an ∼14.8-kb locus involved in antagonistic activity. Only two other environmental isolates were observed to carry the locus, suggesting the presence of additional unique compounds or interactions among other isolates involved in outcompeting P. aeruginosa. This collection of strains represents a source of compounds that are active against multiple pathogenic strains. With the evolution of resistance of P. aeruginosa to currently used antibiotics, these environmental strains provide opportunities for novel compound discovery against drug-resistant clinical strains. IMPORTANCE We demonstrate that clinical CF-derived isolates of P. aeruginosa are susceptible to competition in the presence of environmental pseudomonads. We observed that many diverse environmental strains exhibited varied antagonistic profiles against a panel of clinical P. aeruginosa isolates, suggesting the presence of distinct mechanisms of inhibition among these ecological strains. Understanding the properties of these antagonistic events offers the potential for discoveries of antimicrobial compounds or metabolic pathways important to the development of novel treatments for P. aeruginosa infections. American Society for Microbiology 2016-12-30 /pmc/articles/PMC5203635/ /pubmed/27881418 http://dx.doi.org/10.1128/AEM.02701-16 Text en Copyright © 2016 Chatterjee et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (http://creativecommons.org/licenses/by/4.0/) .
spellingShingle Environmental Microbiology
Chatterjee, Payel
Davis, Elizabeth
Yu, Fengan
James, Sarah
Wildschutte, Julia H.
Wiegmann, Daniel D.
Sherman, David H.
McKay, Robert M.
LiPuma, John J.
Wildschutte, Hans
Environmental Pseudomonads Inhibit Cystic Fibrosis Patient-Derived Pseudomonas aeruginosa
title Environmental Pseudomonads Inhibit Cystic Fibrosis Patient-Derived Pseudomonas aeruginosa
title_full Environmental Pseudomonads Inhibit Cystic Fibrosis Patient-Derived Pseudomonas aeruginosa
title_fullStr Environmental Pseudomonads Inhibit Cystic Fibrosis Patient-Derived Pseudomonas aeruginosa
title_full_unstemmed Environmental Pseudomonads Inhibit Cystic Fibrosis Patient-Derived Pseudomonas aeruginosa
title_short Environmental Pseudomonads Inhibit Cystic Fibrosis Patient-Derived Pseudomonas aeruginosa
title_sort environmental pseudomonads inhibit cystic fibrosis patient-derived pseudomonas aeruginosa
topic Environmental Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5203635/
https://www.ncbi.nlm.nih.gov/pubmed/27881418
http://dx.doi.org/10.1128/AEM.02701-16
work_keys_str_mv AT chatterjeepayel environmentalpseudomonadsinhibitcysticfibrosispatientderivedpseudomonasaeruginosa
AT daviselizabeth environmentalpseudomonadsinhibitcysticfibrosispatientderivedpseudomonasaeruginosa
AT yufengan environmentalpseudomonadsinhibitcysticfibrosispatientderivedpseudomonasaeruginosa
AT jamessarah environmentalpseudomonadsinhibitcysticfibrosispatientderivedpseudomonasaeruginosa
AT wildschuttejuliah environmentalpseudomonadsinhibitcysticfibrosispatientderivedpseudomonasaeruginosa
AT wiegmanndanield environmentalpseudomonadsinhibitcysticfibrosispatientderivedpseudomonasaeruginosa
AT shermandavidh environmentalpseudomonadsinhibitcysticfibrosispatientderivedpseudomonasaeruginosa
AT mckayrobertm environmentalpseudomonadsinhibitcysticfibrosispatientderivedpseudomonasaeruginosa
AT lipumajohnj environmentalpseudomonadsinhibitcysticfibrosispatientderivedpseudomonasaeruginosa
AT wildschuttehans environmentalpseudomonadsinhibitcysticfibrosispatientderivedpseudomonasaeruginosa